https://orcid.org/0000-0002-9976-0530
Figures
Abstract
Background
Recently, the neutrophil-lymphocyte ratio (NLR) has become a biomarker for assessing inflammatory stress and prognosis in different diseases.
Objective
We aimed to conduct a systematic review and meta-analysis to summarize the current evidence on the capacity of the NLR to serve as a biomarker in neuromyelitis optica spectrum disorder (NMOSD).
Methods
Through a comprehensive systematic search up to December 2021 and using the search terms "neutrophil-to-lymphocyte ratio" and "neuromyelitis optica spectrum disorder" we selected studies evaluating NLR values in NMOSD patients. A meta-analysis was planned, and a narrative synthesis was performed when this was not possible. Subgroup and sensitivity analyses were planned. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess certainty of the evidence.
Results
Six studies were included (1036 patients). A significant increase in the NLR was observed between NMOSD patients and healthy controls with high heterogeneity (MD: 1.04; 95% CI: 0.76; 1.32; I2 = 59%). Regarding NMOSD prognosis, relapse (OR: 1.33 –OR: 2.14) was evaluated as being related to NLR with low certainty. An association with Expanded Disability Status Scale (EDSS) score ≥4 (OR: 1.23 –OR: 1.43) was reported with moderate certainty. An association with the occurrence of lesions on MRI was reported with an OR of 1.52.
Citation: Cabanillas-Lazo M, Cruzalegui-Bazán C, Pascual-Guevara M, Quispe-Vicuña C, Terry-Escalante FA, Mori N, et al. (2023) Clinical and imagenologic significance of the neutrophil-to-lymphocyte ratio in neuromyelitis optica spectrum disorder: A systematic review with meta-analysis. PLoS ONE 18(2): e0281064. https://doi.org/10.1371/journal.pone.0281064
Editor: Ralf A. Linker, Friedrich-Alexander University Erlangen, GERMANY
Received: August 26, 2022; Accepted: January 17, 2023; Published: February 9, 2023
Copyright: © 2023 Cabanillas-Lazo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disease of the central nervous system (CNS) characterized by optic neuritis, myelitis and cerebral or brainstem syndromes [1]. Although it is an uncommon pathology with a prevalence of 0.5 per 100,000 inhabitants, NMOSD can increase sixfold in certain racial groups, such as blacks and Asians [1], who are younger at the onset of the disease and develop more NMOSD complications, such as permanent visual impairment and, to a lesser extent, permanent motor disability and wheelchair dependence [2].
Some studies postulate the participation of circulating neuromyelitis optica immunoglobulin G autoantibodies directed against the astrocytic endfeet of AQP-4 [3]; these autoantibodies generate neuronal damage by activating the membrane attack complex, leading to an inflammatory reaction characterized by the presence of neutrophils, eosinophils and macrophages in high proportion but lymphocytes in small proportion [4, 5]. According to a study in which antineutrophil IgG was injected into a group of mice, it was found that in nonneutropenic mice compared to neutropenic mice with greater gravity, there was a larger number of inflamed vessels with adhered neutrophils both luminally and perivascularly that expressed significant loss of myelin and AQP-4. In addition, half of these were active or degranulated neutrophils present in the migration phase, so their presence would be associated with an acute phase of NMOSD [6]. According to another study in which seven patients were analyzed, neutrophils contributed to the pathogenesis of this disease due to their participation in the deregulation of astrocytic function. This occurs through the formation of reactive astrocytes, which contribute to inflammatory processes [7]. Additionally, neutrophils in NMOSD show reduced adhesion and migratory capacity as well as decreased production of reactive oxygen species and degranulation [8].
Therefore, this elevated neutrophil and low lymphocyte participation can be expressed in the neutrophil-lymphocyte ratio (NLR), which, according to recent studies, could be a novel and clinically relevant biomarker used to indicate a higher risk of depression and to predict poor 3-month functional outcomes in ischemic stroke patients [9, 10].
Against this background, the aim of this systematic review is to summarize the current knowledge regarding the capacity of the NLR to serve as a biomarker in NMOSD.
Materials and methods
This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [11]. See S1 Checklist, PRISMA checklist. The study protocol was registered in PROSPERO with the CRD42022306366.
Data sources
We searched PubMed, Embase, Scopus, Web of Science, SciELO Citation Index, and Google Scholar up to December 2021 using the search terms "neutrophil-to-lymphocyte ratio" and "neuromyelitis optica spectrum disorder" The search strategy for PubMed was adapted for use in the other databases (S1 Table). There were no restrictions on language or publication date. We completed the search by reviewing the bibliographic references of the included studies and selecting the articles that met the requirements.
Eligibility criteria
Studies were included if they met the following criteria: 1) studies included adult participants (aged > 18 years old); 2) NLR values were assessed during the pretreatment period in NMOSD patients or controls without NMOSD; and 3) analytical observational studies (cross-sectional, case‒control and cohort studies). We excluded narrative and systematic reviews, studies in nonhumans, case reports, conference abstracts and letters.
Study selection
The electronic search results were imported into Endnote X9, and duplicate records were exported to Rayyan (https://rayyan.qcri.org/). The selection based on the title and abstract was performed by two reviewers (CQV and FTE), and any discrepancies were resolved by consensus and consideration of the opinion of the third reviewer (CAD). These reviewers assessed the inclusion criteria independently by reading the full texts of the potentially relevant studies that were selected, and discrepancies were resolved according to consensus. The complete list of excluded articles is provided in S2 Table.
Outcomes
Our outcomes were as follows: 1) evaluation of NLR (calculated as a simple ratio between the neutrophil and lymphocyte counts measured in peripheral blood) [12] comparing NMOSD patients (diagnosed according to International Diagnostic Criteria Neuromyelitis Optica Spectrum Disorders) [13] with healthy control subjects; and 2) evaluation of NLR at the time of occurrence of at least one of the following events after discharge: 1) relapse (defined as appearance of neurological symptoms or exacerbation of existing neurological symptoms lasting for >24 h, time to the last onset of >1 month, and imaging confirmation of a new lesion); 2) appearance of new/enlarging and/or enhancing lesion on Magnetic Resonance Imaging (MRI); and 3) severity assessment using the Extended Disability Status Scale (EDSS) [14] (which rates the disability status of MS patients on a scale of 0 to 9) with emphasis on level 4.0 (Relatively Severe Disability) and level 7.0 (Essential Wheelchair Restriction).
Typical NMOSD lesions on brain MRI were localized on the optic nerve, brainstem/cerebellum, area postrema, diencephalon and spinal cord (longitudinally extensive transverse myelitis, short-segment transverse myelitis and multisegmented).
Data extraction
Two authors (CCB and FTE) independently carried out data extraction using a data extraction form, and any disagreements were resolved by consensus and, ultimately, by a third author (CAD). We extracted the following information: title of the study, first author, year of publication, study design, country where the study was performed, number of participants, sex, age, sample time, mean or median NLR with standard deviation (SD) according to sample stratification, crude and adjusted association measures, type of outcome and its definition. If additional data were needed, we contacted the corresponding author through email to request further information.
Risk of bias assessment
The quality of the studies was assessed with the Newcastle Ottawa Scale (NOS) [15] by two authors (CCB and FTE). This tool evaluates the quality of published nonrandomized studies and is based on three items: selection, comparability, and outcome/exposure. Each item has subitems to which a star-based score is assigned. Studies with scores ≥ 6 were considered to have a low risk of bias (high quality); those with scores of 4–5 were considered to have a moderate risk of bias; and those with scores of < 4 were considered to have a high risk of bias.
Statistical analysis
A meta-analysis was planned for each outcome; however, when this was not possible due to unavailable data, narrative synthesis was performed. Meta-analysis was performed using a random-effects model. The variance between studies (τ2) was estimated using the DerSimonian‒Laird estimator. Mean differences (MD) with their 95% confidence intervals (CI 95%) between NMOSD patients and controls were pooled. Heterogeneity between studies was assessed using the I2 statistic. Heterogeneity was defined as low if I2 was <30%, moderate if I2 was = 30–60%, and high if I2 was > 60%. The metacont function of the metapackage in R 4.1.0 was used (www.r-project.org). Finally, we performed a subgroup analysis to identify potential sources of heterogeneity and leave-one-out sensitivity analysis.
Evidence certainty assessment
Two authors (CCB and CQV) independently assessed the certainty of our pooled results and qualitative synthesis by applying the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system of rating to continuous outcomes [16] and narrative synthesis [17]. This assessment is based on five domains: study limitations (risk of bias of the studies included), imprecision (sample size and confidence interval), indirectness (generalizability), inconsistency (heterogeneity), and publication bias as stated in the GRADE handbook and GRADE for prognostic factors [18] and in the GRADE adaptation for assessment of evidence about prognosis [19]. We adapted the assessment to our results. The certainty of the evidence was characterized as high, moderate, low, or very low.
Results
Study selection
We identified 376 studies through our systematic search. We removed duplicates and screened 308 studies. Finally, we included 6 articles [20–25] (Fig 1).
Characteristics of studies
All the included studies involved retrospective cohorts. The total number of participants was 1527. A total of 806 participants were NMOSD patients, and 721 were healthy controls. The average age range of NMOSD patients was between 36.29 and 48.71. The summary of the characteristics of the studies is summarized in Table 1.
Risk-of-bias assessment
We assessed the risk of bias of each of the 6 included studies. Five articles had a “low risk of bias.” The study by Lin et al. [22] obtained the lowest score (5/9); the paper did not mention the calculation of the sample, there was no control of confounding variables and adequate follow-up of the cohorts was missing (S3 Table).
NMOSD patients and healthy controls
Among the 6 studies that met our inclusion criteria, three were pooled. A total of 1036 participants were selected, of which 382 were assigned to the NMOSD group and 654 to the control group. In the pooled analysis, a significant increase in the NLR was observed between groups with moderate heterogeneity (MD: 1.04; 95% CI: 0.76; 1.32; I2 = 59%) (Fig 2).
Regarding subgroup analysis between studies with matched patients and controls, we observed that NMOSD patients had a higher NLR than healthy controls in matched studies (MD: 1.18; 95% CI: 0.94; 1.43; I2 = 86%) (MD: 0.81; 95% CI: 0.56; 1.06; I2 = 0%) (Fig 2).
Regarding sensitivity analysis, when single studies were sequentially removed, no variation in the pooled MD was observed, with an effect size of 1.04 in both. This suggests that the results of the meta-analysis were stable (Fig 3).
NMOSD prognosis
Xie et al. and Carnero et al. reported an OR of 1.33 to 2.14 for the relapse outcome. For the EDSS≥4 outcome, an OR of 0.96 to 1.23 was observed. However, these were not determined by meta-analyses because different NLR cutoff points were involved. At the same time, Carnero et al. also reported lesions on MRI as an outcome with an OR of 1.52 (95% CI: 1.14; 2.03) (Table 2).
Evidence certainty
We used GRADE for continuous outcomes in our meta-analysis of NMOSD patients and healthy controls (Table 3). GRADE for narrative synthesis was used in assessing the clinical and radiographic outcomes of NMOSD. We did not downgrade for inconsistency even though I2 was 59% because our subgroup analysis showed that the problem could be due to the case‒control match.
Concerning NMOSD relapse, we judged the certainty as low. We started with a rating of high certainty because all the studies included were cohorts, and we downgraded them according to imprecision and inconsistency. For an EDSS score ≥4, we judged the certainty as moderate. We started with a rating of high certainty because all the studies included were cohorts, and we downgraded because one study was not statistically significant.
Finally, for new lesions, MRI was judged as having moderate certainty. We started with a rating of high certainty because the unique study was a cohort, and we downgraded it according to imprecision (OR: 1.52 [1.14–2.03]) (Table 4).
Discussion
Summary of main results
This systematic review with meta-analysis (1527 participants included) revealed a higher NLR average in NMOSD patients than in healthy controls with high certainty. Furthermore, we found that patients with poor long-term prognoses (NMOSD relapse, moderate incapacity, and new lesions on MRI) had higher NLR values than those who had better results.
NLR in NMOSD patients versus healthy controls
Our pooled analysis showed that the mean NLR was significantly higher in NMOSD patients than in healthy controls. These results were not weakened by any of the studies that reported case‒control matching as the sensitivity analysis showed. This is consistent with previous reviews that also evaluated the NLR in other autoimmune diseases. Wang et al. [26] reported in a meta-analysis of 14 studies that higher NLR values (standardized mean difference [SMD] = 1.43; 95% CI 0.98–1.88; p<0.001) were present in patients with systemic lupus erythematosus than in healthy patients. In addition, Olsson et al. [27] analyzed four case‒control studies and found higher NLR values in MS patients than in healthy controls. Finally, Paliogiannis et al. [28] and Erre et al. [29] reported similar results for psoriasis (SMD = 0.69; 95% CI 0.53–1.85; p<0.001) and rheumatoid arthritis (SMD = 0.79; 95% CI 0.55–1.03; p< 0.001). This would show that high NLR values could be used to differentiate between patients with autoimmune diseases and healthy persons. The mechanism involved in this differentiation could be an imbalance between the number of neutrophils representing innate immune cells and the number of lymphocytes representing acquired immune cells. This is due to the alteration of the permeability of the blood‒brain barrier in neurological diseases [30].
NLR as a prognostic factor in NMOSD patients
This review found the NLR to be a prognostic biochemical marker for relapse, EDSS score ≥4 and presence of lesions by magnetic resonance imaging in patients with NMOSD; this finding is in line with the results of other systematic reviews of patients with MS since the NLR was higher in patients with relapses than in healthy individuals or those with disease in remission [27]. In addition, two of the studies reported cutoff points of 4.52 (sensitivity: 96.1%; specificity: 42.9%) and 3.9 for predicting worse progression of disability assessed as EDSS ≥5 and EDSS >3, respectively. There were no other SRs for NLR and autoimmune neurological diseases; however, there were cohorts in patients with dermatomyositis/polymyositis [31] and systemic lupus erythematosus [27] where NLR was predictive of the overall mortality mainly due to pulmonary complications (cutoff 4.78 and hazard ratio [HR]: 5.20; CI: 1.92–14.07) and development of lupus nephritis (SMD: 0.77; CI: 0.57–0.97). Finally, in pregnant women diagnosed with AQP4-positive NMOSD, an NLR of 5.25 (sensitivity: 72.7%; specificity: 90.0%) was found to predict a pregnancy-related NMOSD attack defined as relapse, onset or worsening of neurological signs, or the presence of a newly enhanced lesion on MRI [32].
Recommendations for future research
The certainty of the evidence for the NLR between NMOSD patients and healthy controls was high. Our subgroup analysis showed that the heterogeneity could be explained by case‒control matching. This could mean that age, gender, or other variables should be identified as confounding variables, so they should be considered in future studies. Otherwise, the certainty of the prognosis was low to moderate due to inconsistency and imprecision. Therefore, prospective studies with appropriate follow-up times and sample sizes are required to determine the precision of the results and validate the NLR cutoff points. In addition, the studies that evaluated prognosis represented South America and China, so we recommend conducting studies in other populations due to heterogeneity in prevalence and clinical manifestations between regions and ethnic groups [33]. Finally, we recommend the development of prognostic modeling studies that consider clinical and biochemical variables such as NLR whose values are easy and inexpensive to obtain and which may be used to predict adverse outcomes with high accuracy in these patients.
Clinical applicability
The NLR is a biomarker of systemic inflammation that has also been shown to be an early diagnostic indicator in cancer [34] and neuroimmune diseases such as MS [27]. Our results indicate that the NLR could serve to both differentiate NMOSD patients from healthy patients and indicate poor long-term prognosis. The latter would support the idea of using the NLR once the diagnosis is established. Otherwise, other possible NMOSD biomarkers have been reported, such as serum levels of cytokines/chemokines and neurofilament light chain [35]. However, all these markers require equipment and advanced preparation for utilization. In this context, the NLR gains clinical importance since it is derived from tests that are simple to perform, inexpensive and routinely available and can be used in conjunction with other clinical or laboratory variables to generate valid predictive models.
Limitations and strengths
Our systematic review has some limitations. First, most of the studies were retrospective in nature, so their results could be susceptible to confounding factors. Second, most studies were conducted in China, which could affect the generalizability of our results. In addition, there was heterogeneity and imprecision in our prognosis outcomes. Despite everything mentioned, this article also has strengths. First, it is innovative in the topic it addresses since it is the first systematic review with meta-analysis that evaluates the prognostic value of the NLR in NMOSD. There were also no restrictions at the time of executing the bibliographic search, so the possibility of publication bias is low. Likewise, we evaluated the certainty of our results with the GRADE approach.
Conclusions
Based on our results, with high certainty, the mean NLR is higher in NMOSD patients than in healthy controls. Furthermore, with low to moderate certainty, we found that the NLR could be a prognostic factor for relapse, disability (EDSS≥4), and appearance of new lesions on MRI. Future prospective studies in different populations and development of prognostic models that take the NLR into account are needed.
Supporting information
S3 Table. Newcastle—Ottawa quality assessment scale for included studies.
https://doi.org/10.1371/journal.pone.0281064.s004
(DOCX)
References
- 1. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11: 501. pmid:32670177
- 2. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135: 1834–1849. pmid:22577216
- 3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202: 473–477. pmid:16087714
- 4. Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012;44: 1519–1530. pmid:22713791
- 5. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130: 1194–1205. pmid:17282996
- 6. Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71: 323–333. pmid:22374891
- 7. Piatek P, Domowicz M, Lewkowicz N, Przygodzka P, Matysiak M, Dzitko K, et al. C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder. Front Immunol. 2018;9. pmid:30083159
- 8. Hertwig L, Pache F, Romero-Suarez S, Stürner KH, Borisow N, Behrens J, et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler. 2016;22: 160–173. pmid:26540731
- 9. Wang C, Zhang Q, Ji M, Mang J, Xu Z. Prognostic value of the neutrophil-to-lymphocyte ratio in acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. BMC Neurol. 2021;21: 191. pmid:33975565
- 10. Cheng Y, Wang Y, Wang X, Jiang Z, Zhu L, Fang S. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Monocyte-to-Lymphocyte Ratio in Depression: An Updated Systematic Review and Meta-Analysis. Frontiers in psychiatry. Switzerland; 2022. p. 893097. pmid:35782448
- 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. pmid:33782057
- 12. Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021;11: 1–9. pmid:33431958
- 13. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85: 177–189. pmid:26092914
- 14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33: 1444–1452. pmid:6685237
- 15. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Ottawa Hosp Res Inst. 2013.
- 16. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—Continuous outcomes. J Clin Epidemiol. 2013;66: 173–183. pmid:23116689
- 17. Murad MH, Mustafa RA, Schünemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017/03/20. 2017;22: 85–87. pmid:28320705
- 18. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev. 2013;2: 71. pmid:24007720
- 19. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ Br Med J. 2015;350: h870. pmid:25775931
- 20. Carnero Contentti E, Delgado-García G, Criniti J, López PA, Pettinicchi JP, Cristiano E, et al. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD. Front Immunol. 2021;12: 1–7. pmid:33717149
- 21. Chen B, Gui MC, Ji SQ, Xie Y, Tian DS, Bu BT. Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System. Neuroimmunomodulation. 2021. pmid:34823248
- 22. Lin J, Xue B, Li J, Xu H, Huang X, Yao Z, et al. Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD. Neurol Sci. 2017;38: 1859–1863. pmid:28779361
- 23. Xie H, Zhao Y, Pan C, Zhang J, Zhou Y, Li Y, et al. Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study. BMC Neurol. 2021;21: 1–13. pmid:34625035
- 24. Zhou Y, Xie H, Zhao Y, Zhang J, Li Y, Duan R, et al. Neutrophil-to-Lymphocyte Ratio on Admission is an Independent Risk Factor for the Severity of Neurological Impairment at Disease Onset in Patients with a First Episode of Neuromyelitis Optica Spectrum Disorder. Neuropsychiatr Dis Treat. 2021;17: 1493–1503. pmid:34040376
- 25. Yangyang Z, Liqin H, Qian Z, Wenyu J. General clinical features and extraneural manifestations of neuromyelitis optica spectrum disorders. 2021; 141–145.
- 26. Wang L, Wang C, Jia X, Yang M, Yu J. Relationship between Neutrophil-to-Lymphocyte Ratio and Systemic Lupus Erythematosus: A Meta-analysis. Clinics (Sao Paulo). 2020;75: e1450–e1450. pmid:32321113
- 27. Olsson A, Gustavsen S, Gisselø Lauridsen K, Chenoufi Hasselbalch I, Sellebjerg F, Bach Søndergaard H, et al. Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review. Acta Neurol Scand. 2021;143: 577–586. pmid:33591593
- 28. Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2019;19: 37–45. pmid:30478648
- 29. Erre GL, Paliogiannis P, Castagna F, Mangoni AA, Carru C, Passiu G, et al. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest. 2019;49: 1–11. pmid:30316204
- 30. Novellino F, Donato A, Malara N, Madrigal JL, Donato G. Complete blood cell count-derived ratios can be useful biomarkers for neurological diseases. International journal of immunopathology and pharmacology. 2021. p. 20587384211048264. pmid:34569352
- 31. Ha Y-J, Hur J, Go DJ, Kang EH, Park JK, Lee EY, et al. Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. PLoS One. 2018;13: e0190411–e0190411. pmid:29293605
- 32. Deng S, Lei Q, Lu W. Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis. Front Immunol. 2022;12: 1–12. pmid:35069584
- 33. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015/04/28. 2015;21: 845–853. pmid:25921037
- 34. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122: 474–488. pmid:34161115
- 35. Okamoto R, Ali Y, Hashizume R, Suzuki N, Ito M. BNP as a Major Player in the Heart-Kidney Connection. Int J Mol Sci. 2019;20. pmid:31336656